» Articles » PMID: 33138310

Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study

Abstract

Ventilator-associated pneumonia (VAP) is a well-known complication of patients on invasive mechanical ventilation. The main cause of acute respiratory distress syndrome (ARDS) is pneumonia. ARDS can occur in patients with community-acquired or nosocomial pneumonia. Data regarding ARDS incidence, related pathogens, and specific outcomes in patients with VAP is limited. This is a cohort study in which patients with VAP were evaluated in an 800-bed tertiary teaching hospital between 2004 and 2016. Clinical outcomes, microbiological and epidemiological data were assessed among those who developed ARDS and those who did not. Forty-one (13.6%) out of 301 VAP patients developed ARDS. Patients who developed ARDS were younger and presented with higher prevalence of chronic liver disease. Pseudomonas aeruginosa was the most frequently isolated pathogen, but without any difference between groups. Appropriate empirical antibiotic treatment was prescribed to ARDS patients as frequently as to those without ARDS. Ninety-day mortality did not significantly vary among patients with or without ARDS. Additionally, patients with ARDS did not have significantly higher intensive care unit (ICU) and 28-day mortality, ICU, and hospital length of stay, ventilation-free days, and duration of mechanical ventilation. In summary, ARDS deriving from VAP occurs in 13.6% of patients. Although significant differences in clinical outcomes were not observed between both groups, further studies with a higher number of patients are needed due to the possibility of the study being underpowered.

Citing Articles

Comprehensive nursing intervention combined with early activityactivity applied in ventilator-associated pneumonia and its influence on blood gas index.

Li Z, Xu L, Wang Y, Gao H Am J Transl Res. 2021; 13(5):5647-5652.

PMID: 34150171 PMC: 8205749.

References
1.
Melsen W, Rovers M, Groenwold R, Bergmans D, Camus C, Bauer T . Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis. 2013; 13(8):665-71. DOI: 10.1016/S1473-3099(13)70081-1. View

2.
Briel M, Meade M, Mercat A, Brower R, Talmor D, Walter S . Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010; 303(9):865-73. DOI: 10.1001/jama.2010.218. View

3.
. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171(4):388-416. DOI: 10.1164/rccm.200405-644ST. View

4.
Millo J, Schultz M, Williams C, Weverling G, Ringrose T, Mackinlay C . Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med. 2003; 30(1):68-74. DOI: 10.1007/s00134-003-2060-0. View

5.
Rello J, Ollendorf D, Oster G, Vera-Llonch M, Bellm L, Redman R . Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002; 122(6):2115-21. DOI: 10.1378/chest.122.6.2115. View